Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jason Bates
University of Vermont & St Agric College, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Oscivallent LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Bates disclosed a significant financial interest (SFI) in Oscivallent. The purpose of Oscivallent is to eventually commercialize technology related to the mechanical ventilation of patients with injured lungs. Professor Bates has been a member of the advisory board of, and a minor shareholder in, Oscillavent since March 2016. The company was just founded in Iowa and has no value to his knowledge.
As a principal investigator, Dr. Bates was awarded a grant “Personalized Mechanical Ventilation for the Injured Lung”. One of the objectives of the grant Is to develop efficient numerical search algorithms for finding minimally injurious ventilation strategies predicted by our computational model of lunch mechanics and injury development.
The relationship between this SFI and the subject of the grant is close enough that a management plan is in the best interest of all parties.
Personalized Mechanical Ventilation for the Injured Lung
Of the 200,000 patients who are diagnosed with acute respiratory distress syndrome (ARDS) each year in the US, about 75,000 will be overwhelmed by their own biological responses. As there are currently no pharmaceutical therapies that have proven efficacious in ARDS, treatment revolves around supportive care centered on mechanical ventilation, but this can lead to ventilator-induced lung injury (VILI) that contributes significanly to ARDS mortality. By identifying personalized strategies for mechanical ventilation that attend to the individual pathophysiological characteristics of a given patient, we will be able to significantly reduce the occurrence of VILI and thus reduce ARDS mortality.
Filed on September 22, 2016.
Tell us what you know about Jason Bates's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jason Bates filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jason Bates | University of Vermont & St Agric College | Conflict of Interest | Oscivallent LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.